- Home
- SACH vs INMB Comparison
SACH vs INMB Comparison
Compare SACH & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SACH
- INMB
- Stock Information
- Founded
- SACH 2010
- INMB 2015
- Country
- SACH United States
- INMB United States
- Employees
- SACH N/A
- INMB N/A
- Industry
- SACH Real Estate Investment Trusts
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- SACH Real Estate
- INMB Health Care
- Exchange
- SACH Nasdaq
- INMB Nasdaq
- Market Cap
- SACH 114.0M
- INMB 123.0M
- IPO Year
- SACH 2017
- INMB 2019
- Fundamental
- Price
- SACH $2.51
- INMB $5.14
- Analyst Decision
- SACH Strong Buy
- INMB Buy
- Analyst Count
- SACH 2
- INMB 1
- Target Price
- SACH $4.25
- INMB $22.00
- AVG Volume (30 Days)
- SACH 235.2K
- INMB 371.2K
- Earning Date
- SACH 11-11-2024
- INMB 10-30-2024
- Dividend Yield
- SACH 16.53%
- INMB N/A
- EPS Growth
- SACH N/A
- INMB N/A
- EPS
- SACH 0.05
- INMB N/A
- Revenue
- SACH $21,298,064.00
- INMB $85,000.00
- Revenue This Year
- SACH N/A
- INMB N/A
- Revenue Next Year
- SACH N/A
- INMB N/A
- P/E Ratio
- SACH $48.35
- INMB N/A
- Revenue Growth
- SACH N/A
- INMB N/A
- 52 Week Low
- SACH $2.22
- INMB $4.81
- 52 Week High
- SACH $4.64
- INMB $14.74
- Technical
- Relative Strength Index (RSI)
- SACH 51.29
- INMB 40.74
- Support Level
- SACH $2.41
- INMB $4.87
- Resistance Level
- SACH $2.47
- INMB $5.73
- Average True Range (ATR)
- SACH 0.08
- INMB 0.29
- MACD
- SACH -0.01
- INMB 0.05
- Stochastic Oscillator
- SACH 45.45
- INMB 35.29
About SACH Sachem Capital Corp.
Sachem Capital Corp is a United States-based real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.